MojiaBio Funding, Investors & Competitors

MojiaBio has raised $238M across 3 funding rounds, most recently a $80M Series B in June 2022.

Last MojiaBio funding round

$80M

Series B · Jun 2022

Cumulative funding MojiaBio raised

$238M

across 3 funding rounds

Key investors in MojiaBio

  • Bits x Bites
  • Asia Green Fund
  • Temasek
  • U.S.-China Green Fund
  • LYZZ Capital
  • Sento Investment

MojiaBio Overview

About MojiaBio

MojiaBio is a synthetic biology firm developing enzyme and metabolic engineering platforms to enhance biomanufacturing sustainability. Headquartered in China, the company optimizes chemical and petroleum processes by replacing polluting catalysts with bio-based alternatives, targeting industries like biofuels and fine chemicals. Its proprietary technologies enable higher yields and lower energy use in fermentation-based production of materials such as bioplastics and pharmaceuticals.


Founded

2018

HQ

ChinaGuang'an

Status

Privately held

Customer focus

B2B

Revenue model

Licensing

MojiaBio Funding History

MojiaBio has raised a total of $238M across 3 funding rounds.

MojiaBio's first fundraising round was a $38M Series A in December 2020. The most recent completed round was a $80M Series B in June 2022.

MojiaBio funding rounds

MojiaBio funding rounds
DateStageInvestorsRaisedDeal Summary
Jun 2022Series BTemasek (lead); Sento Investment; LYZZ Capital; Asia Green Fund; Bits x Bites$80MMojia Bio (also referred to as Mojia Biotech) is a Shanghai-based biomanufacturing company specializing in synthetic biology for green chemical production. It develops a proprietary platform for enzyme and metabolic engineering to produce bio-based ingredients and polymers, starting with vitamin B5 (animal feed additive) using renewable feedstocks that reduce energy use, waste, and emissions compared to petroleum-based methods. The company is expanding into biopolymer products for coating and adhesive applications, addressing supply chain vulnerabilities and China's environmental regulations. On June 23, 2022, Mojia Bio raised $80 million in a Series B round led by Temasek Holdings, with participation from Asia Green Fund, Bits x Bites, LYZZ Capital, and Sento Investment. The funds are allocated to commercialize bio-based animal feed additives like vitamin B5, scale biomanufacturing capacity, advance the product pipeline, and expand global R&D capabilities. Mojia Bio positions itself in the sustainable manufacturing sector, aiming to lead next-generation green chemical production amid global supply chain issues and the shift from fossil fuels. Investors like Bits x Bites highlight its potential to reduce import reliance and support a green economy through innovative bioprocesses.
Sep 2021Series AAsia Green Fund (lead); U.S.-China Green Fund; Bits x Bites$120MMojiaBio is a Singapore-based startup specializing in green chemistry and sustainable biomanufacturing, developing proprietary technologies like Cn+Bio™ pathway and OrthBio® bioconversion process to convert low-cost renewable sources into bio-based molecules as alternatives to petroleum-based chemicals. The company focuses on producing eco-friendly products for various industries, positioning itself in the growing green chemicals market projected to reach USD 200 billion by 2030. Asia Green Fund, a private equity firm with about $2.0 billion in assets under management, has invested in MojiaBio across multiple rounds, including Series A and later Series B. A Series B round on June 23, 2022, raised $80M from investors including Temasek, Asia Green Fund, Bits x Bites, LYZZ Capital, and Sento Investment. Earlier rounds include Series A stages on 3/31/2021, 1/25/2021, and 8/23/2020, also involving Asia Green Fund in some cases. Post-Series B, MojiaBio partnered with Singapore's A*STAR on a S$44.8 million Sustainable Biomanufacturing Technology Platform (SBTP) announced around March 2025 to accelerate commercialization of green products like PDO, supported by Singapore's Green Plan 2030 for biobased chemicals. Asia Green Fund's 2023 and 2024 Green Impact Reports highlight MojiaBio (listed as MOJIABIO) among portfolio companies in green chemistry, emphasizing carbon reduction and sustainable transformation. The firm focuses on impactful investments in industrial upgrades via technological innovation, with MojiaBio noted alongside other greentech firms.
Dec 2020Series AAsia Green Fund; Bits x Bites$38MMojia Bio is a biotech company that has raised a total of $80M across 4 funding rounds, with investors including Asia Green Fund and Bits x Bites. Asia Green Fund participated in rounds from its first funding on 8/23/2020 through Series B in 2022.

Who has invested in MojiaBio?

6 investors have backed MojiaBio across its funding rounds, including Bits x Bites, Asia Green Fund, Temasek, U.S.-China Green Fund, LYZZ Capital and Sento Investment.

Lead investors include Temasek and Asia Green Fund.


MojiaBio Investors

Investors in MojiaBio by funding rounds participated
InvestorHQRoundsRoleFirst check
Asia Green FundChinaChaoyang3LeadDec 2020
Bits x BitesChinaShanghai3ParticipantDec 2020
TemasekSingaporeSingapore1LeadJun 2022
Sento InvestmentChinaBeijing1ParticipantJun 2022

This data is available for Pro users. Sign up to see all 6 MojiaBio investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

MojiaBio Competitors

MojiaBio competitors include listed companies like Borregaard, Tongwei and First Solar, and private ones like PhaBuilder, Absolute and Hydrosat.

Public and private companies comparable to MojiaBio
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
BorregaardNorwayNorwayPublicly listed$807M$169M$1.6B2.2x
PhaBuilderChinaBeijingPrivate--$287M-
TongweiChinaChinaPublicly listed$13B$461M$7.4B1.5x
AbsoluteIndiaNew DelhiPrivate$210M-$500M2.4x
HydrosatUnited StatesWashington, DCPrivate--$180M-
First SolarUnited StatesUnited StatesPublicly listed$5.2B$2.1B$22B4.0x

MojiaBio Public Comps

MojiaBio is still privately-owned, but its public comps include First Solar, CF Industries, Qinghai Salt Lake Industry, Industries Qatar, SABIC Agri-Nutrient, Nextracker, Zhejiang NHU, Tongwei, Baosight and Jinko Solar.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
First Solar$5.2B$2.1B3.8x4.0x9.7x7.7x
CF Industries$7.1B$3.2B3.5x3.1x7.7x6.8x
Qinghai Salt Lake Industry$2.3B$1.2B6.9x4.5x13.3x7.3x
Industries Qatar$4.4B$1.6B3.4x4.4x9.5x14.1x
SABIC Agri-Nutrient$3.5B$1.4B3.8x4.1x9.5x10.1x
Nextracker$3.6B$747M3.2x2.9x15.3x12.9x
Zhejiang NHU$3.3B$1.5B3.5x3.1x7.6x6.7x
Tongwei$13B$461M1.5x1.5x41.6x19.8x

This data is available for Pro users. Sign up to see all MojiaBio competitors and their valuation data.

Start Free Trial

Common questions about MojiaBio

When was MojiaBio founded?MojiaBio was founded in 2018.
Where is MojiaBio headquartered?MojiaBio is headquartered in Guang'an, China.
Is MojiaBio publicly listed?No, MojiaBio is a private, VC-backed company.
How much funding has MojiaBio raised?MojiaBio has raised $238M across 3 funding rounds.
What was MojiaBio's last funding round?MojiaBio's last funding round was a $80M Series B in June 2022, led by Temasek.
Who are MojiaBio's investors?MojiaBio's investors include Asia Green Fund, Bits x Bites, Temasek, Sento Investment, LYZZ Capital and U.S.-China Green Fund.
Which companies are comparable to MojiaBio?Companies comparable to MojiaBio include Borregaard, PhaBuilder, Tongwei, Absolute, Hydrosat and First Solar.

See companies similar to MojiaBio

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial